Relypsa (RLYP) Misses Q4 EPS by 5c; Provides 'Encouraging' Initial Veltassa Script Data

Relypsa (Nasdaq: RLYP) reported Q4 EPS of ($1.40), $0.05 worse than the analyst estimate of ($1.35). Revenue for the quarter came in at $11.96 million versus the consensus estimate of $7.37 million.

Veltassa Progress:

• Relypsa plans to submit a supplemental New Drug Application (sNDA) by mid-2016 requesting a label change for Veltassa based on positive results of Phase 1 drug-drug interaction studies
• Relypsa and VFMCRP on track to submit European application for Veltassa in first half of 2016

Veltassa Demand Update:

Initial demand for Veltassa has been encouraging. Since Veltassa became available on December 21, 2015 through February 12, 2016, 1,229 new outpatient prescriptions were written for Veltassa and received by the company’s hub, Veltassa Konnect. The number of patients who received a free starter-supply of Veltassa, outpatient prescriptions filled and hospital units sold since the launch on December 21, 2015 through February 12, 2016 are detailed below.

For earnings history and earnings-related data on Relypsa (RLYP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat